Psychedelic therapy in Australia used to be limited to the wealthy — that just changed
A $20,000-plus rule kept psychedelic therapy out of reach for everyday Australians — the TGA just scrapped it.
For three years Australia has held a treatment that works, behind a door almost nobody could open. The regulator has now taken one of the heaviest locks off, and the loudest warning that we're "moving too fast" — has been from those profiting off it the most.
It's worth asking who the caution actually serves.
Since 1 July 2023, authorised psychiatrists have been able to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression — the first national pathway of its kind anywhere in the world.
For those two uses the drugs sit in Schedule 8 as controlled medicines; for everything else they stay in Schedule 9, prohibited.
This is medicine delivered under supervision, not a free-for-all.
The early results back that up.
Through late 2025 the program had treated roughly 200 patients with zero serious adverse events officially reported. More than half of the PTSD patients who received MDMA alongside psychotherapy reported significant relief. For people who have cycled through every established treatment without success, that is not a marginal gain.
And almost none of them could get near it.
By last August, only about a dozen psychiatrists in the country had become authorised prescribers. Treatment ran past $20,000 with no Medicare or PBS support. A veteran with treatment-resistant PTSD in regional Victoria had no practical path to a treatment that is technically legal.
The real scandal was never the drugs — it was a system so cautious it functioned as a ban for everyone without money and a city postcode.
The rule that made the sums impossible was the one the TGA has now changed: the prescribing psychiatrist had to stay physically present for the entire session, which can stretch most of a working day.
Remove that, and a session can proceed with an AHPRA-registered practitioner alongside a second staff member, with the psychiatrist no longer chained to the chair for eight hours per patient.
Every other branch of medicine trusts registered professionals to deliver supervised care without a specialist watching every minute.
But the Royal Australian and New Zealand College of Psychiatrists has formally objected, calling it an unjustifiable risk to patient safety. The college is entitled to argue safety. It is also the professional body for the specialists whose mandatory, billable, all-day attendance the old rule guaranteed.
When the people whose required presence made a treatment unaffordable warn against the rule that made it unaffordable, that claim deserves scrutiny, not deference.
The direction is right, and it's overdue. Build the national training accreditation board and the central adverse-event registry the researchers are asking for — back the reform and demand the scaffolding around it.
But a treatment that measurably works should not be walled off to the wealthy few who can absorb a five-figure bill and reach a city hospital.
The wall didn't protect patients. It protected invoices.